rxylt1 Antibody

What is RXYLT1 and why are antibodies against it important for research?

RXYLT1 (formerly known as TMEM5) is a type II transmembrane protein with glycosyltransferase function that plays a critical role in the post-translational modification of α-dystroglycan. RXYLT1 and B4GAT1 modifications serve as primers for extension by LARGE1, which polymerizes the functional matriglycan structure essential for extracellular matrix binding .

Antibodies against RXYLT1 are important research tools as they enable investigation of:

• The role of RXYLT1 in dystroglycanopathies and muscle disorders

• Cardiac muscle t-tubule structural integrity maintenance

• Post-translational modification pathways essential for proper cell-matrix interactions

• Developmental and tissue-specific expression patterns

What are the available types of RXYLT1 antibodies and their applications?

Multiple types of RXYLT1 antibodies are commercially available, with various applications:

Applications include Western blotting (WB), Enzyme-Linked Immunosorbent Assay (ELISA), Flow Cytometry (FC), and Immunohistochemistry (IHC).

How is RXYLT1 protein expressed across different tissues?

RXYLT1 expression varies across tissues, with particular importance in:

• Cardiac muscle, where it plays a role in maintaining t-tubule structural integrity

• Muscle tissues where proper glycosylation of α-dystroglycan is essential

• Brain and neural tissues, as suggested by its inclusion in genomic test panels for rare and inherited disease

Tissue expression profiles can be assessed using antibody-based profiling methods such as immunohistochemistry as documented in resources like The Human Protein Atlas .

What criteria should I consider when selecting an RXYLT1 antibody for my research?

When selecting an RXYLT1 antibody, consider the following factors:

• Application compatibility: Ensure the antibody has been validated for your specific application (WB, ELISA, IHC, FC)

• Species reactivity: Verify the antibody recognizes RXYLT1 in your species of interest (human, mouse, rat)

• Antibody type: Choose between polyclonal (greater epitope coverage) or monoclonal (higher specificity)

• Validated epitope: Check if the antibody targets accessible epitopes in your experimental conditions

• Clonality and host: Consider how these match with other antibodies in multiplexing experiments

• Evidence of validation: Look for antibodies with supporting data in publications or validation repositories

For RXYLT1, several top validated antibodies are available from providers such as Proteintech Group (17095-1-AP), NSJ Bioreagents (RQ8187), and NovoPro Bioscience (116189) .

How can I validate an RXYLT1 antibody for specificity and reproducibility?

To address the challenges of antibody reproducibility , validate your RXYLT1 antibody through:

• Positive and negative controls:

  • Use RXYLT1 knockout models via CRISPR-Cas9 as negative controls

  • Use recombinant RXYLT1 protein as a positive control

  • Include biological samples with known expression levels

• Multi-method validation:

  • Compare results across different detection methods (WB, IHC, ELISA)

  • Confirm with orthogonal methods (e.g., RNA expression data, mass spectrometry)

• Epitope verification:

  • For polyclonal antibodies, verify binding to the intended immunogen sequence

  • For RXYLT1, common immunogens include E.coli-derived human RXYLT1 (Position: H79-K398)

• Cross-reactivity testing:

  • Verify absence of signal in samples lacking RXYLT1

  • Test for potential cross-reactivity with related proteins

• Lot-to-lot consistency:

  • Document antibody performance across different lots

  • Consider recombinant antibodies for improved reproducibility

What are the technical specifications of recombinant RXYLT1 protein for antibody validation?

Recombinant RXYLT1 proteins serve as important positive controls for antibody validation:

This recombinant protein can be used for antibody characterization in Western blotting and ELISA applications .

How should I optimize Western blot protocols for RXYLT1 detection?

For optimal RXYLT1 detection by Western blot:

• Sample preparation:

  • For enrichment of glycoproteins like RXYLT1, use wheat germ agglutinin (WGA) enrichment

  • Process tissue in Tris-buffered saline containing 1% Triton-X-100 with protease inhibitors

  • Combine solubilized fraction with WGA-agarose bead slurry and incubate overnight at 4°C

  • Wash beads and elute with Laemmli sample buffer at 99°C

• Gel separation:

  • Use 3-15% SDS-PAGE gels for optimal separation

  • Transfer to PVDF-FL membranes for fluorescent detection

• Detection conditions:

  • The observed molecular weight of RXYLT1 is approximately 56 kDa

  • Block membranes appropriately (e.g., 5% milk in TBST)

  • Use validated primary antibodies at recommended dilutions

  • Employ appropriate secondary antibodies conjugated to HRP or fluorescent dyes

• Controls:

  • Include positive control (e.g., tissue known to express RXYLT1)

  • Include negative control (e.g., RXYLT1 knockout samples)

  • Consider using recombinant RXYLT1 protein as a reference standard

What immunostaining techniques work best for RXYLT1 localization in tissue samples?

For optimal immunohistochemistry and immunofluorescence detection of RXYLT1:

• Fixation and preparation:

  • Use 4% paraformaldehyde fixation followed by appropriate permeabilization

  • For cardiac tissue, consider cryosectioning to preserve antigen integrity

  • Optimize antigen retrieval methods if paraffin-embedded sections are used

• Primary antibody incubation:

  • Use validated RXYLT1 antibodies at appropriate dilutions

  • Incubate overnight at 4°C for optimal binding

• Visualization strategies:

  • For fluorescence: Use secondary antibodies conjugated to Alexa Fluor dyes (488, 555, 594, or 647)

  • For chromogenic detection: Use HRP-conjugated secondary antibodies with appropriate substrates

• Co-localization studies:

  • RXYLT1 can be co-stained with other markers such as:

    • α-dystroglycan to examine glycosylation patterns

    • Cell membrane markers to confirm transmembrane localization

    • T-tubule markers in cardiac tissue (e.g., JPH2, BIN1, caveolin-3)

• Image acquisition:

  • Use confocal microscopy for precise subcellular localization

  • Capture Z-stacks for three-dimensional reconstruction when necessary

How can RXYLT1 antibodies be used in flow cytometry applications?

For flow cytometry applications with RXYLT1 antibodies:

• Sample preparation:

  • Prepare single-cell suspensions from tissues of interest

  • Fix cells with 2-4% paraformaldehyde

  • Permeabilize with suitable agents (e.g., 0.1% Triton X-100) for intracellular staining

• Antibody selection:

  • Choose RXYLT1 antibodies validated for flow cytometry (e.g., NSJ Bioreagents RQ8187)

  • Consider directly conjugated antibodies or appropriate secondary antibodies

• Staining protocol:

  • Block with appropriate blocking buffer (e.g., 1% BSA in PBS)

  • Incubate with primary antibody at optimal concentration

  • If using indirect detection, incubate with fluorophore-conjugated secondary antibodies

  • Include appropriate controls (isotype, unstained, FMO controls)

• Data acquisition and analysis:

  • Optimize voltage settings for fluorophores used

  • Apply appropriate gating strategies for your cell populations

  • Consider multiparameter analysis with additional markers to identify specific cell subsets

• Troubleshooting:

  • If signal is weak, optimize antibody concentration or try alternative clones

  • If background is high, adjust blocking conditions or try different permeabilization methods

How can RXYLT1 antibodies be used to study glycosylation defects in dystroglycanopathies?

RXYLT1 plays a crucial role in the glycosylation of α-dystroglycan, and antibodies can be powerful tools to study related disorders:

• Functional binding assays:

  • Use laminin overlay assays in conjunction with RXYLT1 and IIH6 (matriglycan) antibodies to assess functional glycosylation

  • Perform the assay by:

    • Blocking PVDF-FL membranes in laminin binding buffer with 5% milk

    • Incubating with mouse Engelbreth-Holm-Swarm laminin overnight at 4°C

    • Using anti-laminin antibodies and appropriate secondary antibodies for detection

• Comparative analysis across models:

  • Compare wild-type, heterozygous, and knockout models for RXYLT1

  • Assess glycosylation status using antibodies against both RXYLT1 and its substrates

  • Evaluate functional consequences using antibodies against downstream interacting proteins

• Therapeutic intervention assessment:

  • Use RXYLT1 antibodies to monitor protein rescue in gene therapy approaches

  • For example, study AAV-mediated RXYLT1 expression as demonstrated with related glycosyltransferases

• Patient sample analysis:

  • Develop diagnostic protocols using RXYLT1 antibodies

  • Compare glycosylation patterns between patient and control samples

How can I use RXYLT1 antibodies in conjunction with active learning approaches for binding prediction?

Integrating RXYLT1 antibodies with advanced computational approaches can enhance research outcomes:

• Library-on-library screening optimization:

  • Utilize RXYLT1 antibodies in experimental validation of computational predictions

  • Implement active learning strategies to reduce the number of required experiments

  • Apply machine learning models to predict antibody-antigen binding using many-to-many relationships

• Validation of computational models:

  • Use experimentally determined binding data from RXYLT1 antibodies to train prediction algorithms

  • Verify out-of-distribution predictions with experimental testing

  • Employ iterative approaches that combine in silico predictions with wet lab validation

• Experimental design considerations:

  • Begin with small labeled subsets and iteratively expand based on active learning approaches

  • Focus on designs that improve experimental efficiency in library-on-library settings

  • Apply algorithms that have shown significant performance improvements over random data labeling

This approach can reduce experimental costs by up to 35% while accelerating the learning process compared to random baseline methods .

What role does RXYLT1 play in cardiac muscle function and how can antibodies help elucidate this?

RXYLT1 has recently been identified as crucial for cardiac muscle function, particularly in t-tubule maintenance:

• Structural analysis of t-tubules:

  • Use RXYLT1 antibodies alongside t-tubule markers (JPH2, BIN1, caveolin-3) to assess structural integrity

  • Compare t-tubule appearance, signal intensity, and fragmentation in control versus RXYLT1-deficient samples

• Functional response to stress:

  • Employ antibodies to monitor RXYLT1 expression and localization during β-adrenergic challenge

  • Assess cardiomyocyte damage using IgG uptake assays in conjunction with RXYLT1 immunostaining

• Matriglycan detection:

  • Use IIH6 antibody to detect matriglycan, the functional glycan structure dependent on RXYLT1 activity

  • Monitor changes in matriglycan levels in disease models or after genetic rescue

• Mechanistic investigations:

  • Examine potential interactions between RXYLT1 and other proteins involved in t-tubule maintenance

  • Study co-localization patterns with other glycosyltransferases in the same pathway

Research has shown that RXYLT1 deficiency leads to disrupted t-tubule appearance, reduced fluorescent signal intensity, and t-tubule loss or fragmentation, particularly under stress conditions .

What are common problems with RXYLT1 antibody experiments and how can they be resolved?

Researchers may encounter several challenges when working with RXYLT1 antibodies:

• Non-specific binding:

  • Problem: Multiple bands or unexpected staining patterns

  • Solution: Use more stringent blocking conditions (5% BSA or 5% milk)

  • Solution: Test different antibody dilutions

  • Solution: Consider using cross-adsorbed secondary antibodies to reduce species cross-reactivity

• Variable results between experiments:

  • Problem: Inconsistent detection of RXYLT1

  • Solution: Standardize sample preparation protocols, especially for glycoprotein enrichment

  • Solution: Document antibody lot numbers and consider single-batch purchases for critical projects

  • Solution: Use recombinant RXYLT1 as a positive control for normalization across experiments

• Low sensitivity:

  • Problem: Weak or absent signal despite expected expression

  • Solution: Optimize antigen retrieval methods for fixed tissues

  • Solution: Try WGA enrichment for glycoprotein samples

  • Solution: Consider signal amplification methods such as tyramide signal amplification

• Batch-to-batch variability:

  • Problem: Different results with same catalog number from different lots

  • Solution: Consider switching to recombinant antibodies for greater consistency

  • Solution: Validate each new lot against previous lots using standardized positive controls

• Detection in specific tissues:

  • Problem: Difficulty detecting RXYLT1 in certain tissues despite expected expression

  • Solution: Optimize tissue-specific fixation and preparation methods

  • Solution: Consider alternative antibody clones that recognize different epitopes

How can I implement rigorous quality control for RXYLT1 antibody experiments?

Implementing rigorous quality control measures is essential for reliable RXYLT1 antibody experiments:

• Antibody validation workflow:

  • Validate each new antibody lot before use in critical experiments

  • Document validation results in laboratory records

  • Include validation results in research publications

• Control inclusion:

  • Always include positive controls (tissues/cells known to express RXYLT1)

  • Include negative controls (RXYLT1 knockout/knockdown samples)

  • For quantification methods, include blank samples (buffer only) to establish baseline

• Technical replicates:

  • Perform at least three technical replicates for quantitative experiments

  • Ensure consistent sample loading and transfer efficiency for Western blots

  • Use internal loading controls appropriate for your experimental conditions

• Cross-method validation:

  • Confirm key findings with multiple detection methods (e.g., WB, IHC, qPCR)

  • Consider orthogonal approaches that don't rely on antibodies (e.g., mass spectrometry)

• Documentation practices:

  • Record complete antibody information (catalog number, lot number, concentration)

  • Document all experimental conditions and image acquisition parameters

  • Maintain raw data alongside processed results

What emerging technologies might improve RXYLT1 antibody reliability and reproducibility?

Several emerging technologies show promise for improving antibody reliability and addressing the reproducibility crisis :

• Recombinant antibody production:

  • Sequence-defined antibodies produced from plasmids ensure consistent properties

  • Eliminates batch-to-batch variability inherent in hybridoma and animal-derived antibodies

  • Allows for precise engineering of antibody properties and conjugation sites

• Antibody sequencing technologies:

  • De novo protein sequencing of successful antibodies enables recreation as recombinant versions

  • Preserves valuable antibody clones if hybridomas are lost

  • Creates permanent, reproducible reagents from previously variable sources

• CRISPR-based validation:

  • Generate precise knockout controls using CRISPR-Cas9 targeting of RXYLT1

  • Develop engineered cell lines with tagged RXYLT1 for antibody validation

  • Create isogenic cell lines with varied RXYLT1 expression levels

• Advanced binding prediction tools:

  • Use computational approaches to predict epitope-paratope interactions

  • Apply active learning strategies to optimize antibody development

  • Integrate structural biology data with antibody engineering

• Standardized reporting:

  • Adopt minimum reporting standards for antibody experiments (e.g., RRID identifiers)

  • Participate in antibody validation repositories

  • Include complete antibody metadata in publications